Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Heerim Nam 5 Articles
Head and Neck cancer
Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx
Heerim Nam, Yong Chan Ahn, Kyungmi Yang, Dongryul Oh, Jae Myoung Noh
Cancer Res Treat. 2022;54(1):96-108.   Published online March 26, 2021
DOI: https://doi.org/10.4143/crt.2020.1349
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to analyze the treatment outcomes of locally recurrent nasopharyngeal cancer (NPC) patients following moderate hypo-fractionation re-irradiation (re-RT).
Materials and Methods
Sixty locally recurrent NPC patients underwent hypo-fractionation re-RT. Forty-eight point three percentage had rT3-4, and 30.0% did keratinizing squamous cell carcinoma. Intensity-modulated radiation therapy (IMRT), with or without intensity-modulated proton therapy (IMPT), was used in 66.7% of patients.
Results
With the median follow-up of 22 months (range, 2 to 254 months), 31 patients (51.7%) died, 38 (63.3%) developed further treatment failure, and 30 (50.0%) developed ≥ grade 3 toxicity (including seven grade 5) at time of analysis. The 2- and 5-year rates of overall survival, local failure-free survival, and ≥ grade 3 toxicity-free survival were 57.9% and 45.8%, 64.1% and 52.5%, and 54.8% and 44.9%, respectively. In multivariate analyses, worse factors for overall survival (OS) were iT3-4 (p=0.010) and age at re-RT ≥ 53 years (p=0.003), those for local failure-free survival (LFFS) were rT3-4 (p=0.022) and rN0-1 (p=0.035), and those for toxicity-free survival (TFS) were iT3-4 (p=0.020) and re-IMRT/IMPT (p=0.030), respectively. Cumulative dose or fraction size ≥ 3 Gy at re-RT, however, showed no significance for OS, LFFS and TFS.
Conclusion
Current re-RT with modern RT techniques by moderate hypo-fractionation scheme seemed feasible in treating locally recurrent NPC patients.

Citations

Citations to this article as recorded by  
  • Radiation oncology for the rhinologist
    Helena Levyn, Fan Yang, Nancy Y. Lee
    Current Opinion in Otolaryngology & Head & Neck Surgery.2024; 32(1): 5.     CrossRef
  • Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma
    Zi-Jian Lu, Ting Liu, Jie-Yi Lin, Sheng-Ting Pei, Ling Guo, Sai-Lan Liu, Hai-Qiang Mai
    Radiotherapy and Oncology.2023; 183: 109635.     CrossRef
  • Low-dose radiotherapy effects the progression of anti-tumor response
    Lei Gao, Anqi Zhang
    Translational Oncology.2023; 35: 101710.     CrossRef
  • The Role of Hypofractionation in Proton Therapy
    Alexandre Santos, Scott Penfold, Peter Gorayski, Hien Le
    Cancers.2022; 14(9): 2271.     CrossRef
  • Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
    Xingzhe Li, Sarin Kitpanit, Anna Lee, Dennis Mah, Kevin Sine, Eric J. Sherman, Lara A. Dunn, Loren S. Michel, James Fetten, Kaveh Zakeri, Yao Yu, Linda Chen, Jung Julie Kang, Daphna Y. Gelblum, Sean M. McBride, Chiaojung J. Tsai, Nadeem Riaz, Nancy Y. Lee
    JAMA Network Open.2021; 4(6): e2113205.     CrossRef
  • 6,429 View
  • 197 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Hematologic malignancy
Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma
Jong Yun Baek, Do Hoon Lim, Dongryul Oh, Heerim Nam, Jae J Kim, Jun Haeng Lee, Byung-Hoon Min, Hyuk Lee
Cancer Res Treat. 2022;54(1):294-300.   Published online April 1, 2021
DOI: https://doi.org/10.4143/crt.2021.073
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma.
Materials and Methods
This retrospective study included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region who were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution. Of total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (control group). A diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes event (DE) were defined as HbA1c level of ≥ 6.5%.
Results
During the median follow-up of 49 months, no local failure occurred after RT and no patients died of lymphoma. The RT group had significantly higher risk for DAEs on univariable analysis (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.64 to 10.66; p < 0.01) and multivariable analysis (HR, 3.68; 95% CI, 1.42 to 9.56; p=0.01). Further, the DE risk was significantly higher in the RT group than in the control group (HR, 4.32; 95% CI, 1.08 to 17.30; p=0.04) and in patients with increased baseline HbA1c levels (HR, 35.83; 95% CI, 2.80 to 459.19; p=0.01). On multivariable analysis, RT significantly increased the risk of DEs (HR, 4.55; 95% CI, 1.08 to 19.19; p=0.04), even after adjusting baseline HbA1c level (HR, 40.97; 95% CI, 3.06 to 548.01; p=0.01).
Conclusion
Patients who received RT for gastroduodenal indolent lymphoma had an increased risk of diabetes compared to those who did not.

Citations

Citations to this article as recorded by  
  • CHARACTERISTICS OF ENDOCRINE COMPONENT OF PANCREAS AFTER ADMINISTRATION OF N-ACETYLCYSTEINE IN THE MODEL OF ACUTE RADIATION-INDUCED PANCREATITIS
    Grigoriy Aleksandrovich Demyashkin, Dali Ibragimovna Ugurchieva, Vladislav Andreevich Yakimenko, Matvey Anatol'evich Vadyukhin
    Ulyanovsk Medico-biological Journal.2024; (2): 166.     CrossRef
  • ASSESSMENT OF THE INFLAMMATORY RESPONSE IN THE PANCREAS AFTER ADMINISTRATION OF N-ACETYL CYSTEINE IN A MODEL OF POST-RADIATION PANCREATITIS
    G.A. Demyashkin, D.A. Atyakshin, D.I. Ugurchieva, V.A. Yakimenko, M.A. Vadyukhin, S.N. Koryakin
    Molekulyarnaya Meditsina (Molecular medicine).2024; : 58.     CrossRef
  • Lactobacillus gasseriCKCC1913 mediated modulation of the gut–liver axis alleviated insulin resistance and liver damage induced by type 2 diabetes
    Shuaiming Jiang, Aijie Liu, Wenyao Ma, Xinlei Liu, Pengfei Luo, Meng Zhan, Xiaoli Zhou, Lihao Chen, Jiachao Zhang
    Food & Function.2023; 14(18): 8504.     CrossRef
  • Consumption of ultra-processed foods and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study
    Reynalda Cordova, Vivian Viallon, Emma Fontvieille, Laia Peruchet-Noray, Anna Jansana, Karl-Heinz Wagner, Cecilie Kyrø, Anne Tjønneland, Verena Katzke, Rashmita Bajracharya, Matthias B. Schulze, Giovanna Masala, Sabina Sieri, Salvatore Panico, Fulvio Ricc
    The Lancet Regional Health - Europe.2023; 35: 100771.     CrossRef
  • Risk of Diabetes Mellitus after Radiotherapy for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Joongyo Lee, Hong In Yoon, Jihun Kim, Jaeho Cho, Kyung Hwan Kim, Chang-Ok Suh
    Cancers.2022; 14(17): 4110.     CrossRef
  • 6,475 View
  • 125 Download
  • 2 Web of Science
  • 5 Crossref
Close layer
Feasibility of Selective Neck Irradiation with Lower Elective Radiation Dose in Treating Nasopharynx Cancer Patients
Won Kyung Cho, Dongryul Oh, Eonju Lee, Tae Gyu Kim, Hyebin Lee, Heerim Nam, Jae Myoung Noh, Yong Chan Ahn
Cancer Res Treat. 2019;51(2):603-610.   Published online July 18, 2018
DOI: https://doi.org/10.4143/crt.2018.240
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to report the clinical outcomes following selective neck irradiation (SNI) with lower elective radiation therapy (RT) dose in treating nasopharyngeal cancer (NPC) patients.
Materials and Methods
A total of 347 NPC patients received definitive RT according to our SNI policy and were retrospectively analyzed. The clinical target volumes (CTVs) were subdivided into CTV at high risk (CTV-HR) and CTV at low risk (CTV-LR). The typical doses to gross tumor volume (GTV), CTV-HR, and CTV-LR were 68.4-70.0 Gy, 54.0-60.0 Gy, and 36.0 Gy.
Results
With the median follow-up of 68.1 months (range, 2.3 to 197.1 months), the 5-year rates of loco-regional control and progression-free survival in all the patients were 85.0% and 70.8%, respectively. Thirty patients developed regional failure and the regional control rates at 3 and 5 years were 92.6% and 91.4%, respectively. The sites of regional failure in relation to the target volume were exclusively inside GTV/CTV-HR in 20, inside and outside GTV/CTVHR in three, and exclusively outside GTV/CTV-HR in seven, which were 5.7%, 0.9%, and 2.0% of total patients, respectively.
Conclusion
The clinical outcomes by the current SNI policy were feasible and comparable to those following classic elective nodal irradiation policy.

Citations

Citations to this article as recorded by  
  • In Reply to Liu and Luo
    Kangpyo Kim, Yong Chan Ahn
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(1): 308.     CrossRef
  • Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance
    Yang Liu, Wenbin Yan, Chaosu Hu, Xiaodong Huang, Kai Wang, Yuan Qu, Xuesong Chen, Runye Wu, Ye Zhang, Jianghu Zhang, Jingwei Luo, Yexiong Li, Jingbo Wang, Junlin Yi
    Clinical Cancer Research.2024; 30(9): 1801.     CrossRef
  • Dosimetric Comparison and Selection Criteria of Intensity-Modulated Proton Therapy and Intensity-Modulated Radiation Therapy for Adaptive Re-Plan in T3-4 Nasopharynx Cancer Patients
    Mincheol Ko, Kyungmi Yang, Yong Chan Ahn, Sang Gyu Ju, Dongryul Oh, Yeong-bi Kim, Dong Yeol Kwon, Seyjoon Park, Kisung Lee
    Cancers.2024; 16(19): 3402.     CrossRef
  • Less is more: level IB-sparing radiation therapy in nasopharyngeal cancer
    Dongryul Oh
    Radiation Oncology Journal.2023; 41(1): 1.     CrossRef
  • Dose and volume de-escalation of radiotherapy in head and neck cancer
    MJ García-Anaya, S. Segado-Guillot, J. Cabrera-Rodríguez, MD Toledo-Serrano, JA Medina-Carmona, J. Gómez-Millán
    Critical Reviews in Oncology/Hematology.2023; 186: 103994.     CrossRef
  • Can Definitive Radiation Therapy Substitute Surgical Resection in Locally Advanced T3 or T4 Sinonasal Squamous Cell Carcinoma?
    Kangpyo Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Han-Sin Jeong, Man Ki Chung, Sang Duk Hong, Chung-Hwan Baek
    International Journal of Radiation Oncology*Biology*Physics.2023; 117(4): 893.     CrossRef
  • Progress in the comprehensive treatment of nasopharyngeal carcinoma: a review for risk-stratified management strategies
    Yang Liu, Ziou Du, Shiyu Song, Junlin Yi
    Holistic Integrative Oncology.2023;[Epub]     CrossRef
  • Involved site radiation therapy in stage I-III nasopharyngeal carcinoma with limited lymph node burden (ISRT-NPC) or elective region irradiation: a study protocol for a multicenter non-inferiority randomized controlled phase III clinical trial
    Yang Liu, Yaqian Han, Feng Liu, Desheng Hu, Zhijian Chen, Peiguo Wang, Jingao Li, Jiyong Qin, Feng Jin, Yexiong Li, Jingbo Wang, Junlin Yi
    BMC Cancer.2023;[Epub]     CrossRef
  • The Metabolic Footprint of Systemic Effects in the Blood Caused by Radiotherapy and Inflammatory Conditions: A Systematic Review
    Karol Jelonek, Katarzyna Mrowiec, Dorota Gabryś, Piotr Widłak
    Metabolites.2023; 13(9): 1000.     CrossRef
  • Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment
    Donghyeok Kim, Nalee Kim, Sungmin Koh, Man Ki Chung, Young-Ik Son, Dongryul Oh, Han-Sin Jeong, Yong Chan Ahn
    Cancer Research and Treatment.2022; 54(1): 84.     CrossRef
  • Re-irradiation with Moderate Hypo-fractionation Using Intensity Modulated Photon or Proton Radiation Therapy in Locally Recurrent Squamous Cell Carcinoma of Nasopharynx
    Heerim Nam, Yong Chan Ahn, Kyungmi Yang, Dongryul Oh, Jae Myoung Noh
    Cancer Research and Treatment.2022; 54(1): 96.     CrossRef
  • Risk of Stroke in Nasopharyngeal Cancer Survivors
    Teng Hwee Tan, Huili Zheng, Timothy Cheo, Jeremy Tey, Yu Yang Soon
    Neurology.2022;[Epub]     CrossRef
  • High Superior-Middle Pharyngeal Constrictor Muscle Mean Dose Correlates with Severe Late Lung Infection and Survival in Nasopharyngeal Cancer Patients
    Wen-Shan Liu, Ju-Chun Chien, Yu-Hsien Huang, Po-Chun Chen, Wei-Lun Huang, Shao-Wei Chiang, Ching-Chih Lee, Bor-Hwang Kang, Yu-Chang Hu
    Cancer Management and Research.2022; Volume 14: 1063.     CrossRef
  • Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients
    Wen-Shan Liu, Kuo-Wang Tsai, Bor-Hwang Kang, Ching-Chieh Yang, Wei-Lun Huang, Ching-Chih Lee, Yu-Chang Hu, Kuo-Ping Chang, Hsiu-Min Chen, Yaoh-Shiang Lin
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 495.     CrossRef
  • Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients
    Kyungmi Yang, Yong Chan Ahn, Heerim Nam, Sang Duk Hong, Dongryul Oh, Jae Myoung Noh
    Oral Oncology.2021; 114: 105180.     CrossRef
  • Early Clinical Outcomes of Intensity Modulated Radiation Therapy/Intensity Modulated Proton Therapy Combination in Comparison with Intensity Modulated Radiation Therapy Alone in Oropharynx Cancer Patients
    Han Gyul Yoon, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Seung Gyu Park, Heerim Nam, Sang Gyu Ju, Dongyeol Kwon, Seyjoon Park
    Cancers.2021; 13(7): 1549.     CrossRef
  • Contemporary management of the neck in nasopharyngeal carcinoma
    Wai Tong Ng, Raymond K. Y. Tsang, Jonathan J. Beitler, Remco de Bree, Andrés Coca‐Pelaz, Avraham Eisbruch, Orlando Guntinas‐Lichius, Anne W. M. Lee, Antti A. Mäkitie, William M. Mendenhall, Sandra Nuyts, Alessandra Rinaldo, K. Thomas Robbins, Juan P. Rodr
    Head & Neck.2021; 43(6): 1949.     CrossRef
  • Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
    Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
    Cancer Research and Treatment.2021; 53(3): 657.     CrossRef
  • Advances in cancer imaging require renewed radiotherapy dose and target volume concepts
    Johannes H.A.M. Kaanders, Sven van den Bosch, Tim Dijkema, Abrahim Al-Mamgani, Cornelis P.J. Raaijmakers, Wouter V. Vogel
    Radiotherapy and Oncology.2020; 148: 140.     CrossRef
  • Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer
    Seung Gyu Park, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Sang Gyu Ju, Dongyeol Kwon, Kwanghyun Jo, Kwangzoo Chung, Eunah Chung, Woojin Lee, Seyjoon Park
    Cancer Science.2019; 110(9): 2867.     CrossRef
  • 7,424 View
  • 213 Download
  • 21 Web of Science
  • 20 Crossref
Close layer
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
Kyung Hwa Lee, Yong Chan Ahn, Hongryull Pyo, Jae Myoung Noh, Seung Gyu Park, Tae Gyu Kim, Eonju Lee, Heerim Nam, Hyebin Lee, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
Cancer Res Treat. 2019;51(2):769-776.   Published online September 11, 2018
DOI: https://doi.org/10.4143/crt.2018.366
AbstractAbstract PDFPubReaderePub
Purpose
This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer.
Materials and Methods
Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course.
Results
The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade ≥ 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED10) (≥ 79.2 Gy10 vs. < 79.2 Gy10; hazard ratio [HR], 0.431), smaller CTV (≤ 80 cm3 vs. > 80 cm3; HR, 0.403), and longer disease-free interval (> 1 year vs. ≤ 1 year; HR, 0.489) were significantly favorable factors for OS.
Conclusion
The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED10, smaller CTV, and longer disease-free interval were favorable factors for improved survival.

Citations

Citations to this article as recorded by  
  • Prognosis of non‐small cell lung cancer with postoperative regional lymph node recurrence
    Yoichi Ohtaki, Toshiteru Nagashima, Naoko Okano, Nobuteru Kubo, Takeru Ohtaka, Noriaki Sunaga, Reiko Sakurai, Yosuke Miura, Seshiru Nakazawa, Natsuko Kawatani, Tomohiro Yazawa, Ryohei Yoshikawa, Eiji Narusawa, Ken Shirabe
    Thoracic Cancer.2024; 15(11): 859.     CrossRef
  • Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056)
    Megumi Furuta, Hidehito Horinouchi, Isao Yokota, Teppei Yamaguchi, Shoichi Itoh, Takafumi Fukui, Akira Iwashima, Jun Sugisaka, Yu Miura, Hisashi Tanaka, Taichi Miyawaki, Hiroshi Yokouchi, Keita Miura, Ryota Saito, Go Saito, Tatsuhiko Kamoshida, Yusuke Uch
    Cancer Science.2024; 115(11): 3705.     CrossRef
  • Impact of lymphadenectomy extent on immunotherapy efficacy in post-resectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study
    Hongsheng Deng, Juan Zhou, Hualin Chen, Xiuyu Cai, Ran Zhong, Feng Li, Bo Cheng, Caichen Li, Qingzhu Jia, Caicun Zhou, René Horsleben Petersen, Gaetano Rocco, Alex Brunelli, Calvin S.H. Ng, Thomas A. D’Amico, Chunxia Su, Jianxing He, Wenhua Liang, Bo Zhu
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
    Kathleen Bowes, Nick Jovanoski, Audrey E. Brown, Danilo Di Maio, Rossella Belleli, Shkun Chadda, Seye Abogunrin
    Medical Oncology.2022;[Epub]     CrossRef
  • Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
    Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
    Radiation Oncology Journal.2021; 39(1): 24.     CrossRef
  • Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017)
    NaiBin Chen, QiWen Li, SiYu Wang, Mai Xiong, YiFeng Luo, Bin Wang, Li Chen, MaoSheng Lin, XiaoBo Jiang, JianLan Fang, SuPing Guo, JinYu Guo, Nan Hu, XinLei Ai, DaQuan Wang, Chu Chu, FangJie Liu, Hao Long, JunYe Wang, Bo Qiu, Hui Liu
    Lung Cancer.2021; 156: 82.     CrossRef
  • Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience
    Yoon Young Jo, Su Ssan Kim, Si Yeol Song, Eun Kyung Choi
    Radiation Oncology Journal.2021; 39(3): 210.     CrossRef
  • Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy
    Cole Friedes, Nicholas Mai, Wei Fu, Chen Hu, Peijin Han, Kristen A. Marrone, K. Ranh Voong, Russell K. Hales
    Lung Cancer.2020; 145: 119.     CrossRef
  • 9,347 View
  • 226 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Tumor Volume Reduction Rate during Adaptive Radiation Therapy as a Prognosticator for Nasopharyngeal Cancer
Hyebin Lee, Yong Chan Ahn, Dongryul Oh, Heerim Nam, Jae Myoung Noh, Su Yeon Park
Cancer Res Treat. 2016;48(2):537-545.   Published online July 14, 2015
DOI: https://doi.org/10.4143/crt.2015.081
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the prognostic significance of the tumor volume reduction rate (TVRR) measured during adaptive definitive radiation therapy (RT) for nasopharyngeal cancer (NPC).
Materials and Methods
We reviewed the RT records of 159 NPC patients treated with definitive RT with or without concurrent chemotherapy between January 2006 and February 2013. Adaptive re-planning was performed in all patients at the third week of RT. The pre- and mid-RT gross tumor volumes (GTVs) of the primary tumor and the metastatic lymph nodes were measured and analyzed for prognostic implications.
Results
After a median follow-up period of 41.5 months (range, 11.2 to 91.8 months) for survivors, there were 43 treatment failures. The overall survival and progression-free survival (PFS) rates at 5 years were 89.6% and 69.7%, respectively. The mean pre-RT GTV, mid-RT GTV, and TVRR were 45.9 cm3 (range, 1.5 to 185.3 cm3), 26.7 cm3 (1.0 to 113.8 cm3), and –41.9% (range, –87% to 78%), respectively. Patients without recurrence had higher TVRR than those with recurrence (44.3% in the no recurrence group vs. 34.0% in the recurrence group, p=0.004), and those with TVRR > 35% achieved a significantly higher rate of PFS at 5 years (79.2% in TVRR > 35% vs. 53.2% in TVRR ≤ 35%; p < 0.001). In multivariate analysis, TVRR was a significant factor affecting PFS (hazard ratio, 2.877; 95% confidence interval, 1.555 to 5.326; p=0.001).
Conclusion
TVRR proved to be a significant prognostic factor in NPC patients treated with definitive RT, and could be used as a potential indicator for early therapeutic modification during the RT course.

Citations

Citations to this article as recorded by  
  • Risk stratification of LA‐NPC during chemoradiotherapy based on clinical classification and TVRR
    Qianlong Tang, Chaorong Mei, Bei Huang, Rui Huang, Le Kang, Ailin Chen, Na lei, Pengcheng Deng, Shouyan Ying, Peng Zhang, Yuan Qin
    Cancer Medicine.2024;[Epub]     CrossRef
  • Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view
    Sandra Nuyts, Heleen Bollen, Avrahram Eisbruch, Primoz Strojan, William M. Mendenhall, Sweet Ping Ng, Alfio Ferlito
    Cancer Medicine.2024;[Epub]     CrossRef
  • Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study
    Jun-Mei Song, Ning Mo, Yu-Qing Lv, Lu-Lu Huang, Ya-Jing Wen, Ting Liu, Zhi-Ru Li, Ren-Sheng Wang, Ting-Ting Zhang
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma
    Xiate Zhou, Tianchi Shao, Haijian Jia, Liqiao Hou, Xingni Tang, Changhui Yu, Chao Zhou, Suna Zhou, Haihua Yang
    Oral Oncology.2024; 158: 107008.     CrossRef
  • Evaluating psychological anxiety in patients receiving radiation therapy using smartwatch
    Sangwoon Jeong, Chanil Jeon, Dongyeon Lee, Won Park, Hongryull Pyo, Youngyih Han
    Radiation Oncology Journal.2024; 42(2): 148.     CrossRef
  • Dosimetric Comparison and Selection Criteria of Intensity-Modulated Proton Therapy and Intensity-Modulated Radiation Therapy for Adaptive Re-Plan in T3-4 Nasopharynx Cancer Patients
    Mincheol Ko, Kyungmi Yang, Yong Chan Ahn, Sang Gyu Ju, Dongryul Oh, Yeong-bi Kim, Dong Yeol Kwon, Seyjoon Park, Kisung Lee
    Cancers.2024; 16(19): 3402.     CrossRef
  • Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma
    Qian Chen, Liangfang Shen, Shan Li
    European Archives of Oto-Rhino-Laryngology.2023; 280(5): 2497.     CrossRef
  • Automated tracking of morphologic changes in weekly magnetic resonance imaging during head and neck radiotherapy
    Eric Aliotta, Yu‐Chi Hu, Peng Zhang, Phillip Lichtenwalner, Amanda Caringi, Natasha Allgood, C. Jillian Tsai, Kaveh Zakeri, Nancy Lee, Pengpeng Zhang, Laura Cerviño, Michalis Aristophanous
    Journal of Applied Clinical Medical Physics.2023;[Epub]     CrossRef
  • Nomograms incorporating primary tumor response at mid‐radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma
    Xixi Liu, Jing Huang, You Qin, Zhanjie Zhang, Bian Wu, Kunyu Yang
    Head & Neck.2023; 45(8): 1922.     CrossRef
  • Tumor Volume Reduction Rate to Induction Chemotherapy is a Prognostic Factor for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study
    Ting-Chun Lin, Chi-Hsien Huang, Ming-Yu Lien, Fu-Ming Cheng, Kai-Chiun Li, Chih-Yuan Lin, Ying-Chun Lin, Ji-An Liang, Ti-Hao Wang
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Assessment of dose gradient index variation during simultaneously integrated boost intensity‐modulated radiation therapy for head and neck cancer patients
    Salam Abdulrazzaq Ibrahim Al‐Rawi, Hassan Abouelenein, Mohamad El‐Sayed EL Nagdy, Haidar Hamza Alabdei, Awf Abdulrahman Sulaiman, Dalya Saad Al‐Nuaimi, Magdy Mohammed Khalil, Ahmed Salih Alshewered
    Precision Radiation Oncology.2022; 6(3): 216.     CrossRef
  • Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients
    Kyungmi Yang, Yong Chan Ahn, Heerim Nam, Sang Duk Hong, Dongryul Oh, Jae Myoung Noh
    Oral Oncology.2021; 114: 105180.     CrossRef
  • Early Clinical Outcomes of Intensity Modulated Radiation Therapy/Intensity Modulated Proton Therapy Combination in Comparison with Intensity Modulated Radiation Therapy Alone in Oropharynx Cancer Patients
    Han Gyul Yoon, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Seung Gyu Park, Heerim Nam, Sang Gyu Ju, Dongyeol Kwon, Seyjoon Park
    Cancers.2021; 13(7): 1549.     CrossRef
  • Semi-Automatic Volumetric and Standard Three-Dimensional Measurements for Primary Tumor Evaluation and Response to Treatment Assessment in Pediatric Rhabdomyosarcoma
    Ewelina Gowin, Katarzyna Jończyk-Potoczna, Patrycja Sosnowska-Sienkiewicz, Anna Belen Larque, Paweł Kurzawa, Danuta Januszkiewicz-Lewandowska
    Journal of Personalized Medicine.2021; 11(8): 717.     CrossRef
  • Residual Volume of Lymph Nodes During Chemoradiotherapy Based Nomogram to Predict Survival of Nasopharyngeal Carcinoma Patient Receiving Induction Chemotherapy
    Yan Li, Jian Zang, Jingyi Liu, Shanquan Luo, Jianhua Wang, Bingxin Hou, Lina Zhao, Mei Shi
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Adaptive radiotherapy for head and neck cancer
    Howard E. Morgan, David J. Sher
    Cancers of the Head & Neck.2020;[Epub]     CrossRef
  • Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma
    Huiyun Yang, Yuanyuan Liu, Rongjun Zhang, Yaomin Ye, Qiuqiu Chen, Qinghua Qin, Liying Huang, Xi Li, Rui Cai, Huaying Tang, Wei Jiang
    Oral Oncology.2020; 110: 104897.     CrossRef
  • The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
    Yuan-Yuan Zeng, Zhong-Zheng Xiang, Tao He, Fang Liu, Bian-Fei Shao, Ruo-Nan Yan, Jia-Chun Ma, Xi-Ran Wang, Lei Liu
    Oral Oncology.2020; 111: 104924.     CrossRef
  • Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy
    Sik-Kwan Chan, Sum-Yin Chan, Horace Cheuk-Wai Choi, Chi-Chung Tong, Ka-On Lam, Dora Lai-Wan Kwong, Varut Vardhanabhuti, To-Wai Leung, Mai-Yee Luk, Anne Wing-Mui Lee, Victor Ho-Fun Lee
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients
    Pei-Jing Li, Kai-Xin Li, Ting Jin, Hua-Ming Lin, Jia-Ben Fang, Shuang-Yan Yang, Wei Shen, Jia Chen, Jiang Zhang, Xiao-Zhong Chen, Ming Chen, Yuan-Yuan Chen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Radiotherapy for Head and Neck Cancer: Evaluation of Triggered Adaptive Replanning in Routine Practice
    Metin Figen, Didem Çolpan Öksüz, Evrim Duman, Robin Prestwich, Karen Dyker, Kate Cardale, Satiavani Ramasamy, Patrick Murray, Mehmet Şen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The prognostic value of volumetric reduction of the target lesions after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
    Zhong‐zheng Xiang, Fang Liu, Ruo‐nan Yan, Yuan‐yuan Zeng, Tao He, Zhen Zeng, Zhi‐hui Zhu, Long Bai, Jia‐chun Ma, Lei Liu
    Head & Neck.2019; 41(6): 1863.     CrossRef
  • Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management
    Yong Chan Ahn
    Radiation Oncology Journal.2019; 37(2): 67.     CrossRef
  • Early clinical outcomes of helical tomotherapy/intensity‐modulated proton therapy combination in nasopharynx cancer
    Seung Gyu Park, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Sang Gyu Ju, Dongyeol Kwon, Kwanghyun Jo, Kwangzoo Chung, Eunah Chung, Woojin Lee, Seyjoon Park
    Cancer Science.2019; 110(9): 2867.     CrossRef
  • Pretreatment Prediction of Adaptive Radiation Therapy Eligibility Using MRI-Based Radiomics for Advanced Nasopharyngeal Carcinoma Patients
    Ting-ting Yu, Sai-kit Lam, Lok-hang To, Ka-yan Tse, Nong-yi Cheng, Yeuk-nam Fan, Cheuk-lai Lo, Ka-wa Or, Man-lok Chan, Ka-ching Hui, Fong-chi Chan, Wai-ming Hui, Lo-kin Ngai, Francis Kar-ho Lee, Kwok-hung Au, Celia Wai-yi Yip, Yong Zhang, Jing Cai
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Which nasopharyngeal cancer patients need adaptive radiotherapy?
    Yu-Chang Hu, Kuo-Wang Tsai, Ching-Chih Lee, Nan-Jing Peng, Ju-Chun Chien, Hsin-Hui Tseng, Po-Chun Chen, Jin-Ching Lin, Wen-Shan Liu
    BMC Cancer.2018;[Epub]     CrossRef
  • 12,813 View
  • 146 Download
  • 28 Web of Science
  • 26 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP